Global Obesity Treatment Market
Marktgröße in Milliarden USD
CAGR :
% 
USD
38.46 Million
USD
115.26 Million
2024
2032
 Prognosezeitraum |
2025 –2032 |
 Marktgröße (Basisjahr) | USD 38.46 Million |
 Marktgröße (Prognosejahr) | USD 115.26 Million |
 CAGR |
% |
| Wichtige Marktteilnehmer |
Globale Marktsegmentierung für die Behandlung von Fettleibigkeit nach Behandlungstyp (pharmakologische Behandlungen (Medikamente gegen Fettleibigkeit), bariatrische Chirurgie, Verhaltens- und Lebensstiltherapie, nicht-invasive/endoskopische Verfahren sowie medizinische Geräte und Technologien), Altersgruppe (Behandlung von Fettleibigkeit bei Erwachsenen, Behandlung von Fettleibigkeit bei älteren Menschen und Behandlung von Fettleibigkeit bei Kindern), Vertriebskanal (Online-Apotheken, Einzelhandelsapotheken, Kliniken für Gewichtsmanagement, Krankenhausapotheken sowie Wellness- und Fitnesszentren), Patiententyp (Klasse III, Klasse II und Klasse I) – Branchentrends und Prognose bis 2032
Marktgröße für die Behandlung von Fettleibigkeit
- Der globale Markt für Adipositasbehandlungen wurde im Jahr 2024 auf 38,46 Millionen US-Dollar geschätzt und soll bis 2032 115,26 Millionen US-Dollar erreichen.
- Im Prognosezeitraum von 2025 bis 2032 wird der Markt voraussichtlich mit einer durchschnittlichen jährlichen Wachstumsrate von 14,7 % wachsen , was vor allem auf die zunehmende Verbreitung von Fettleibigkeit zurückzuführen ist.
- Dieses Wachstum wird durch Faktoren wie Innovationen bei Medikamenten gegen Fettleibigkeit und das Wachstum bei bariatrischen und metabolischen Operationen vorangetrieben. Darüber hinaus wird die Integration digitaler Gesundheitslösungen in die Fettleibigkeitsbehandlung vorangetrieben.
Marktanalyse zur Behandlung von Fettleibigkeit
- Fettleibigkeit ist eine chronische Erkrankung, die durch übermäßige Fettansammlung gekennzeichnet ist und das Risiko schwerer gesundheitlicher Komplikationen wie Herz-Kreislauf-Erkrankungen, Typ-2-Diabetes, Bluthochdruck und bestimmter Krebsarten erhöht.
- Die Behandlungsmöglichkeiten reichen von Änderungen des Lebensstils, Pharmakotherapie und medizinischen Geräten bis hin zur bariatrischen Chirurgie mit dem Ziel, eine nachhaltige Gewichtsabnahme zu erreichen und den allgemeinen Gesundheitszustand zu verbessern.
- Der globale Markt für Adipositasbehandlungen wird durch die zunehmende Verbreitung von Fettleibigkeit aufgrund von Bewegungsmangel, ungesunder Ernährung und genetischer Veranlagung angetrieben. Pharmakologische Interventionen, darunter GLP-1-Rezeptoragonisten und Appetitzügler, spielen neben Verhaltenstherapie und Lebensstiländerungen eine entscheidende Rolle bei der Gewichtskontrolle. Auch bariatrische Operationen wie Magenbypass und Schlauchmagenbildung gewinnen als wirksame Langzeitlösungen bei schwerer Adipositas an Bedeutung.
- Die steigende Nachfrage nach minimalinvasiven Verfahren und innovativen Medikamenten gegen Fettleibigkeit treibt das Marktwachstum weiter voran
- Nordamerika bleibt eine dominierende Region auf dem globalen Markt für Adipositasbehandlungen, unterstützt durch eine gut etablierte Gesundheitsinfrastruktur, hohe Adipositasraten und kontinuierliche Forschung an Lösungen zur Gewichtskontrolle.
- So sind die USA beispielsweise führend bei der Einführung von GLP-1-Rezeptoragonisten wie Semaglutid und Liraglutid, und es gibt auch Fortschritte bei nicht-invasiven medizinischen Geräten zur Gewichtsabnahme.
- Mit der zunehmenden Betonung der Adipositas-Behandlung und der präventiven Gesundheitsfürsorge erlebt der globale Markt erhebliche Investitionen in neuartige Therapien, Medizintechnik und patientenorientierte Lösungen, was die allgemeine Expansion der Branche vorantreibt.
Berichtsumfang und Marktsegmentierung für die Behandlung von Fettleibigkeit
|
Eigenschaften |
Wichtige Markteinblicke zur Behandlung von Fettleibigkeit |
|
Abgedeckte Segmente |
|
|
Abgedeckte Länder |
Nordamerika .
Europa
Asien-Pazifik
Südamerika
Naher Osten und Afrika
|
|
Wichtige Marktteilnehmer |
|
|
Marktchancen |
|
|
Wertschöpfungsdaten-Infosets |
Zusätzlich zu den Einblicken in Marktszenarien wie Marktwert, Wachstumsrate, Segmentierung, geografische Abdeckung und wichtige Akteure enthalten die von Data Bridge Market Research kuratierten Marktberichte auch Import-Export-Analysen, eine Übersicht über die Produktionskapazität, eine Analyse des Produktionsverbrauchs, eine Preistrendanalyse, ein Szenario des Klimawandels, eine Lieferkettenanalyse, eine Wertschöpfungskettenanalyse, eine Übersicht über Rohstoffe/Verbrauchsmaterialien, Kriterien für die Lieferantenauswahl, eine PESTLE-Analyse, eine Porter-Analyse und regulatorische Rahmenbedingungen. |
Markttrends zur Behandlung von Fettleibigkeit
Steigende Akzeptanz digitaler und KI-gesteuerter Lösungen zur Gewichtskontrolle
- Ein wichtiger Trend auf dem globalen Markt für die Behandlung von Fettleibigkeit ist die zunehmende Nutzung digitaler und KI-gesteuerter Lösungen zur Gewichtskontrolle
- Diese innovativen Technologien verbessern das Adipositas-Management, indem sie personalisierte Behandlungspläne, Echtzeit-Überwachung und datenbasierte Erkenntnisse zur Optimierung von Gewichtsverluststrategien bereitstellen.
- So erfassen beispielsweise KI-gestützte mobile Anwendungen und tragbare Geräte körperliche Aktivitäten, Kalorienaufnahme und Stoffwechselraten und bieten maßgeschneiderte Empfehlungen zur Verbesserung der Therapietreue und der Ergebnisse.
- Telemedizin-Plattformen und virtuelles Coaching unterstützen Patienten zusätzlich durch Fernkonsultationen, Verhaltensberatung und Medikamentenmanagement, was zu einer effektiveren und nachhaltigeren Gewichtsabnahme führt
- Dieser Trend revolutioniert die Adipositasbehandlung, indem er die Patienteneinbindung verbessert, den langfristigen Behandlungserfolg steigert und die Nachfrage nach digitalen Gesundheitslösungen auf dem Markt für Adipositasbehandlungen ankurbelt.
Marktdynamik zur Behandlung von Fettleibigkeit
Treiber
Zunehmende Prävalenz von Fettleibigkeit
- Die Fettleibigkeitsepidemie nimmt aufgrund von Bewegungsmangel, schlechten Ernährungsgewohnheiten und genetischer Veranlagung zu, was zu einem starken Anstieg von gewichtsbedingten Gesundheitskomplikationen wie Diabetes, Herz-Kreislauf-Erkrankungen und Bluthochdruck führt.
- Urbanisierung und technologischer Fortschritt haben zu einer verringerten körperlichen Aktivität beigetragen, während der weit verbreitete Konsum von verarbeiteten und kalorienreichen Lebensmitteln die Gewichtszunahme weiter begünstigt hat.
- Auch genetische Faktoren spielen eine wichtige Rolle. Viele Menschen neigen zu Stoffwechselstörungen, die zu Fettleibigkeit führen. Da die Fettleibigkeitsraten weiter steigen, steigt die Nachfrage nach wirksamen Behandlungslösungen, darunter pharmakologische Therapien, bariatrische Operationen und medizinisch überwachte Gewichtsmanagementprogramme, deutlich an.
Zum Beispiel
- Laut WHO-Informationen eskaliert die Adipositas-Epidemie in Europa im März 2024. Im Jahr 2022 wird jeder Achte Mensch von Adipositas betroffen sein. Die Adipositas bei Erwachsenen hat sich seit 1990 verdoppelt, bei Jugendlichen sogar vervierfacht. Über 2,5 Milliarden Erwachsene sind übergewichtig, darunter 890 Millionen Adipositas-Patienten. Steigende Adipositasraten erhöhen das Risiko für Diabetes, Herzerkrankungen und Krebs, was die Nachfrage nach wirksamen Behandlungen steigert und das Marktwachstum ankurbelt.
- Wie die Centers for Disease Control and Prevention (CDC) im September 2024 hervorhoben, litten zwischen August 2021 und August 2023 40,3 % der Erwachsenen an Adipositas, davon 39,2 % der Männer und 41,3 % der Frauen. Die höchste Prävalenz war bei Erwachsenen im Alter von 40–59 Jahren (46,4 %) zu verzeichnen, gefolgt von den Altersgruppen 20–39 (35,5 %) und 60+ (38,9 %). Die zunehmende Adipositasbelastung dürfte die Nachfrage nach wirksamen Adipositasbehandlungen steigern.
- Wie der World Obesity Atlas bereits im Jahr 2024 berichtet, werden bis 2035 79 % der übergewichtigen und adipösen Erwachsenen und 88 % der übergewichtigen und adipösen Kinder in Ländern mit niedrigem und mittlerem Einkommen (LMICs) leben. Die Zahl der Erwachsenen mit Adipositas wird voraussichtlich von 0,81 Milliarden im Jahr 2020 auf 1,53 Milliarden im Jahr 2035 steigen. Diese steigende Prävalenz erhöht die Nachfrage nach Behandlungslösungen für Adipositas und treibt das Marktwachstum voran.
- Diese wachsende Patientenbelastung veranlasst Gesundheitsdienstleister, Pharmaunternehmen und Wellness-Programme dazu, ihre Angebote zu erweitern. Die zunehmende Verbreitung von Fettleibigkeit ist somit ein wichtiger Treiber für den europäischen Markt für Fettleibigkeitsbehandlungen.
Gelegenheit
Zunehmende Prävalenz lebensstilbedingter Krankheiten
- Da immer mehr Menschen versuchen, ihr Gewicht zu kontrollieren und die damit verbundenen Gesundheitsrisiken zu minimieren, werden Pharmaunternehmen und Gesundheitsdienstleister dazu angehalten, ihr Angebot zu erneuern und zu erweitern.
- Dieser Trend fördert die Entwicklung neuer Medikamente, chirurgischer Optionen und umfassender Lifestyle-Programme, die auf die unterschiedlichen Bedürfnisse der Patienten zugeschnitten sind.
Zum Beispiel
- Im Mai 2023 gab das NCBI bekannt, dass bis 2030 schätzungsweise mehr als eine Milliarde Menschen an Fettleibigkeit leiden werden.1 Die höheren Sterblichkeitsraten und Komorbiditäten, die mit Fettleibigkeit in Zusammenhang stehen, wie Diabetes, Herz-Kreislauf-Erkrankungen, chronische Nierenerkrankungen und verschiedene Krebsarten, sind ebenso erschreckend: Im Durchschnitt sind es 5 Millionen Todesfälle und 160 Millionen behinderungsbereinigte Lebensjahre.
- Laut einem im Juni 2023 von Acta Pharmaceutica Sinica B veröffentlichten Artikel trägt Fettleibigkeit stark zur Entstehung von Krebs, Herz-Kreislauf-Erkrankungen, Typ-2-Diabetes, Lebererkrankungen und anderen Erkrankungen bei
- Laut einem im April 2021 in den American Heart Association Journals veröffentlichten Artikel trägt Fettleibigkeit direkt zu kardiovaskulären Risikofaktoren bei, darunter Dyslipidämie, Typ-2-Diabetes, Bluthochdruck und Schlafstörungen. Fettleibigkeit führt auch unabhängig von anderen kardiovaskulären Risikofaktoren zur Entwicklung von Herz-Kreislauf-Erkrankungen und zur Sterblichkeit durch Herz-Kreislauf-Erkrankungen.
- Im April 2023 stellte eine Studie von MoneyControl fest, dass Indien einen massiven Anstieg von Zivilisationskrankheiten erlebt hat, darunter eine Zunahme früher Risikofaktoren wie Fettleibigkeit und Cholesterinunregelmäßigkeiten.
- Darüber hinaus fördert das gestiegene Bewusstsein für die gesundheitlichen Folgen von Fettleibigkeit ein proaktives Gesundheitsmanagement bei den Verbrauchern. Dank unterstützender Initiativen von Regierungen und Gesundheitsorganisationen zur Förderung eines gesünderen Lebensstils steht der Markt für Fettleibigkeitsbehandlungen vor einem erheblichen Wachstum.
- Diese Dynamik zieht Investitionen an und fördert die Forschungs- und Entwicklungsanstrengungen. Sie ebnet den Weg für eine breite Palette therapeutischer Interventionen, um den Bedürfnissen einer wachsenden Patientenpopulation gerecht zu werden.
Einschränkung/Herausforderung
Langzeit-Follow-ups im Zusammenhang mit der Behandlung von Fettleibigkeit
- Langfristige Nachuntersuchungen im Zusammenhang mit der Behandlung von Fettleibigkeit erfordern aufgrund der Komplexität und Ressourcenintensität solcher Programme häufig eine kontinuierliche Überwachung und Unterstützung, um eine nachhaltige Gewichtsabnahme und -kontrolle zu gewährleisten. Dazu können regelmäßige Konsultationen, Ernährungsberatung und Verhaltenstherapie gehören.
- Diese langfristigen Verpflichtungen belasten die Gesundheitssysteme und stellen sowohl für Patienten als auch für Leistungserbringer eine logistische Herausforderung dar, was zu potenziellen Versorgungslücken und einer inkonsistenten Therapietreue führen kann.
Zum Beispiel
- Im Dezember 2022 erfordert die Behandlung von Fettleibigkeit laut AJMC die kontinuierliche Partnerschaft eines engagierten Patienten und informierter Ärzte. Die Behandlung von Fettleibigkeit erfordert die kontinuierliche Partnerschaft eines engagierten Patienten und informierter Ärzte
- Im September 2022 berichtete JAMA Network, dass in einer Studie mit 175 Patienten 94 (53,7 %) nach drei Monaten einen Gewichtsverlust von mindestens 5 % und 26 (14,9 %) von 10 % oder mehr verzeichneten. Von 102 Patienten, die sechs Monate lang nachbeobachtet wurden, erreichten 89 (87,3 %) einen Gewichtsverlust von 5 % oder mehr, 56 (54,9 %) einen Gewichtsverlust von 10 % oder mehr, 24 (23,5 %) einen Gewichtsverlust von 15 % oder mehr und 8 (7,8 %) einen Gewichtsverlust von 20 % oder mehr.
- Laut einem im November 2021 veröffentlichten Artikel der National Library of Medicine scheint die Sicherstellung einer langfristigen Nachsorge für bariatrische Patienten von größter Bedeutung zu sein. Eine schlechte Nachsorgequalität in der bariatrischen Chirurgie gilt als Risikofaktor für schlechte Ergebnisse, aber die Vielseitigkeit und Effektivität der Nachsorge sind auch entscheidende Faktoren für die klinische Forschung.
- Darüber hinaus schreckt die Notwendigkeit langfristiger Nachuntersuchungen Betroffene zunächst von einer Behandlung ab. Viele potenzielle Patienten scheuen den Aufwand und die Kosten, die mit regelmäßigen Kontrolluntersuchungen und Überwachungen verbunden sind, und empfinden dies als entmutigend oder unbequem.
- Dieses Zögern behindert das Marktwachstum, da potenzielle Verbraucher vor Programmen zurückschrecken, die nachhaltiges Engagement und Verantwortlichkeit erfordern.
- Folglich kann die Herausforderung, wirksame Langzeitnachuntersuchungen zu ermöglichen, die allgemeine Wirksamkeit von Adipositasbehandlungen und ihre Akzeptanz in der Zielgruppe einschränken.
Marktumfang der Fettleibigkeitsbehandlung
Der Markt ist nach Typ, Produkttyp, Absorptionsort, Altersgruppe, Quelle, Liefermethode, Geschlecht und Vertriebskanal segmentiert.
|
Segmentierung |
Untersegmentierung |
|
|
|
|
|
|
|
|
Regionale Analyse des Marktes für die Behandlung von Fettleibigkeit
Nordamerika ist die dominierende Region im Insulinmarkt für Typ-1- und Typ-2-Diabetes
- Nordamerika ist weltweit führend auf dem Markt für Adipositasbehandlungen. Die Gründe dafür liegen in der hohen Prävalenz von Adipositas, der fortschrittlichen Gesundheitsinfrastruktur und der starken Akzeptanz innovativer Lösungen zur Gewichtskontrolle.
- Die USA verfügen über einen bedeutenden Marktanteil aufgrund der steigenden Nachfrage nach pharmakologischen Behandlungen wie GLP-1-Rezeptoragonisten, bariatrischen Operationen und digitalen Plattformen zur Gewichtskontrolle.
- Darüber hinaus treiben das zunehmende Bewusstsein für die mit Fettleibigkeit verbundenen Gesundheitsrisiken und die zunehmende Nutzung von KI-gesteuerten Gewichtsverlustprogrammen, Telemedizin-Beratungen und nicht-invasiven Behandlungslösungen die Marktexpansion in der Region weiter voran.
Südamerika wird voraussichtlich die höchste Wachstumsrate verzeichnen
- In der südamerikanischen Region wird auf dem globalen Markt für die Behandlung von Fettleibigkeit voraussichtlich die höchste Wachstumsrate verzeichnet werden. Grund hierfür sind die zunehmende Verbreitung von Fettleibigkeit, steigende Investitionen im Gesundheitswesen und ein wachsendes Bewusstsein für Lösungen zur Gewichtskontrolle.
- Länder wie Brasilien, Argentinien und Chile entwickeln sich aufgrund veränderter Lebensstile, zunehmender Urbanisierung und einer steigenden Zahl von gesundheitlichen Komplikationen im Zusammenhang mit Fettleibigkeit zu Schlüsselmärkten.
- Brasilien bleibt mit seiner wachsenden Gesundheitsinfrastruktur und der steigenden Nachfrage nach medizinischen Behandlungen zur Gewichtsreduktion ein wichtiger Markt für die Behandlung von Adipositas. Das Land erlebt eine zunehmende Akzeptanz pharmakologischer Behandlungen, bariatrischer Operationen und digitaler Gewichtsmanagementprogramme.
Marktanteil der Adipositasbehandlung
Die Wettbewerbslandschaft des Marktes bietet detaillierte Informationen zu den einzelnen Wettbewerbern. Zu den Details gehören Unternehmensübersicht, Finanzdaten, Umsatz, Marktpotenzial, Investitionen in Forschung und Entwicklung, neue Marktinitiativen, globale Präsenz, Produktionsstandorte und -anlagen, Produktionskapazitäten, Stärken und Schwächen des Unternehmens, Produkteinführung, Produktbreite und -umfang sowie Anwendungsdominanz. Die oben genannten Datenpunkte beziehen sich ausschließlich auf die Marktausrichtung der Unternehmen.
Die wichtigsten Marktführer auf dem Markt sind:
- Novo Nordisk A/S (Dänemark)
- Eli Lilly and Company (USA)
- Medtronic (USA)
- Boston Scientific Corporation (USA)
- Johnson & Johnson Services, Inc. (USA)
- Altimmune (USA)
- AstraZeneca (Großbritannien)
- Allurion (USA)
- Amgen Inc. (USA)
- Arena Pharmaceuticals Ltd (USA)
- Currax Pharmaceuticals LLC (USA)
- COUSIN-CHIRURGIE (Frankreich)
- F. Hoffmann-La Roche Ltd (Schweiz)
- Fitterfly Healthtech Pvt. Ltd. (Indien)
- Morphic Medical, Inc (USA)
- Noom, Inc. (USA)
- Omada Health Inc (USA)
- Reshape Lifesciences Inc. (USA)
- Raziel (Isarel)
- Spatz FGIA Inc. (US)
- Sanofi (Frankreich)
- Saniona (Dänemark)
- USGI Medical (USA)
- VIVUS LLC. (USA)
- Viking Therapeutics (USA)
Neueste Entwicklungen auf dem globalen Markt für Adipositasbehandlung
- Im Oktober 2024 haben VIVUS und UpScriptHealth ChooseQ. online eingeführt, eine Telemedizin-Plattform, die bequemen Zugang zu QSYMIA zur Gewichtskontrolle bietet. Dieser Service ermöglicht es Patienten, sich online mit Gesundheitsdienstleistern zu beraten und QSYMIA direkt zu Hause zu erhalten. Diese Initiative zielt darauf ab, den Zugang zur Adipositas-Behandlung durch Telemedizin zu verbessern.
- Im Oktober 2024 gab Zealand Pharma bekannt, dass Boehringer Ingelheim von der US-amerikanischen Arzneimittelzulassungsbehörde FDA den Status einer bahnbrechenden Therapie für Survodutide (BI 456906) zur Behandlung von nicht-zirrhotischer, metabolischer Dysfunktion-assoziierter Steatohepatitis (MASH) mit mittelschwerer oder fortgeschrittener Fibrose erhalten hat. Dieser Status beschleunigt die Entwicklung des Medikaments aufgrund vielversprechender Ergebnisse der Phase II.
- Im März 2025 gab Zealand Pharma den Abschluss der Teilnehmerrekrutierung für die Phase-2b-Studie ZUPREME-1 für Petrelintid bekannt, ein langwirksames Amylinanalogon zur Behandlung von Übergewicht und Adipositas. Die Studie untersucht die Auswirkungen verschiedener Dosierungen von Petrelintid auf Körpergewicht, Sicherheit und Verträglichkeit über 42 Wochen. Ergebnisse werden für 2025 erwartet.
- Im März 2025 gab Raziel Therapeutics, ein Pharmaunternehmen, das sich auf verschreibungspflichtige Produkte der nächsten Generation für den Markt der medizinischen Ästhetik konzentriert, den Beginn einer klinischen Phase-3-Studie in China für RZL-012 bekannt, die auf die Reduzierung von submentalem Fett (SMF) abzielt. Die SMF-Reduktion ist die erste Indikation für RZL-012 und bietet potenzielle Anwendungen für verschiedene ästhetische Fettreduktionsbehandlungen zur Körperformung.
- Im Oktober 2022 gab ReShape Lifesciences, ein führendes Unternehmen im Bereich Gewichtsverlust und Stoffwechselgesundheit, bekannt, dass die American Society for Metabolic and Bariatric Surgery (ASMBS) und die International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) aktualisierte Richtlinien für die metabolische und bariatrische Chirurgie veröffentlicht haben, die nun auch das Magenband umfassen. Diese Richtlinien ersetzen die 30 Jahre alten Standards der National Institutes of Health (NIH) aus dem Jahr 1991.
SKU-
Erhalten Sie Online-Zugriff auf den Bericht zur weltweit ersten Market Intelligence Cloud
- Interaktives Datenanalyse-Dashboard
- Unternehmensanalyse-Dashboard für Chancen mit hohem Wachstumspotenzial
- Zugriff für Research-Analysten für Anpassungen und Abfragen
- Konkurrenzanalyse mit interaktivem Dashboard
- Aktuelle Nachrichten, Updates und Trendanalyse
- Nutzen Sie die Leistungsfähigkeit der Benchmark-Analyse für eine umfassende Konkurrenzverfolgung
Inhaltsverzeichnis
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL OBESITY TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY: GLOBAL OBESITY TREATMENT MARKET
4.4 DRUG TREATMENT RATE BY MATURED MARKETS: GLOBAL OBESITY TREATMENT MARKET
4.5 DRUG
4.6 WORD PIPELINE
5 REGULATORY FRAMEWORK FOR THE GLOBAL OBESITY TREATMENT MARKET
5.1 REGULATORY APPROVAL PATHWAYS
5.2 LICENSING AND REGISTRATION
5.3 REGULATORY APPROVAL PATHWAYS
5.4 LICENSING AND REGISTRATION
5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF OBESITY
6.1.2 INNOVATIONS IN ANTI-OBESITY MEDICATIONS
6.1.3 GROWTH IN BARIATRIC AND METABOLIC SURGERIES.
6.1.4 INTEGRATION OF DIGITAL HEALTH SOLUTIONS IN OBESITY TREATMENT
6.2 RESTRAINTS
6.2.1 ANTI-OBESITY DRUGS AND SURGICAL INTERVENTIONS CARRY RISKS
6.2.2 HIGH RELAPSE RATES POST-TREATMENT OF OBESITY
6.3 OPPORTUNITIES
6.3.1 INCREASING PREVALENCE OF LIFESTYLE RELATED DISEASES
6.3.2 RISING DISPOSABLE INCOME ENHANCING THE PURCHASING POWER FOR OBESITY TREATMENT RELATED PRODUCTS
6.3.3 RISE IN STRATEGIC INITIATIVES AND LAUNCHES BY MARKET PLAYERS
6.4 CHALLENGES
6.4.1 LONG-TERM FOLLOW-UPS ASSOCIATED WITH OBESITY TREATMENT
6.4.2 ADDRESSAL OF THE LIFESTYLE AND BEHAVIORAL CHANGES
7 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS)
7.2.1 GLP-1 RECEPTOR AGONISTS
7.2.2 DUAL GIP/ GLP-1 RECEPTOR AGONISTS
7.2.2.1 PHENTERMINE
7.2.2.2 PHENTERMINE-TOPIRAMATE
7.2.2.3 NALTREXONE-BUPROPION
7.2.3 LIPASE INHIBITORS
7.2.4 DEOXYCHOLIC ACID
7.2.5 OTHERS
7.3 BARIATRIC SURGERY
7.3.1 RESTRICTIVE SURGERIES
7.3.1.1 SLEEVE GASTRECTOMY
7.3.1.2 ADJUSTABLE GASTRIC BANDING
7.3.2 COMBINATION SURGERIES
7.3.2.1 ROUX-EN-Y GASTRIC BYPASS (RYGB)
7.3.2.2 MINI-GASTRIC BYPASS (MGB)
7.3.3 MALABSORPTIVE SURGERIES
7.3.3.1 LAPAROSCOPIC SURGERY
7.3.3.2 ROBOTIC-ASSISTED SURGERY
7.3.3.3 OPEN SURGERY
7.4 BEHAVIORAL & LIFESTYLE THERAPY
7.4.1 DIETARY INTERVENTIONS
7.4.2 BEHAVIORAL MODIFICATION THERAPY
7.4.3 PHYSICAL ACTIVITY PROGRAMS
7.4.4 PSYCHOLOGICAL COUNSELING
7.5 NON-INVASIVE/ ENDOSCOPIC PROCEDURES
7.5.1 ENDOSCOPIC SLEEVE GASTROPLASTY (ESG)
7.5.2 INTRAGASTRIC BALLOON (IGB)
7.5.2.1 ORBERA INTRAGASTRIC BALLOON
7.5.2.2 SPATZ ADJUSTABLE BALLOON SYSTEM
7.5.3 ASPIRATION THERAPY (ASPIREASSIST)
7.5.4 TRANSORAL GASTROPLASTY (TOGA)
7.6 MEDICAL DEVICES & TECHNOLOGIES
7.6.1 ARTIFICIAL INTELLIGENCE & DIGITAL WEIGHT MANAGEMENT PLATFORMS
7.6.2 GASTRIC ELECTRICAL STIMULATION DEVICES (MAESTRO SYSTEM)
8 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP
8.1 OVERVIEW
8.2 ADULT OBESITY TREATMENT
8.3 GERIATRIC OBESITY TREATMENT
8.4 PEDIATRIC OBESITY TREATMENT
9 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL
9.1 OVERVIEW
9.2 ONLINE PHARMACIES
9.3 RETAIL PHARMACIES
9.4 WEIGHT MANAGEMENT CLINICS
9.5 HOSPITAL PHARMACIES
9.6 WELLNESS & FITNESS CENTERS
10 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 CLASS III
10.3 CLASS II
10.4 CLASS I
11 GLOBAL OBESITY TREATMENT MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 U.S.
11.2.2 MEXICO
11.2.3 CANADA
11.3 EUROPE
11.3.1 UNITED KINGDOM
11.3.2 GERMANY
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 RUSSIA
11.3.7 TURKEY
11.3.8 NETHERLANDS
11.3.9 SWITZERLAND
11.3.10 POLAND
11.3.11 IRELAND
11.3.12 AUSTRIA
11.3.13 NORWAY
11.3.14 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 CHINA
11.4.2 JAPAN
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 TAIWAN
11.4.7 SINGAPORE
11.4.8 MALAYSIA
11.4.9 THAILAND
11.4.10 INDONESIA
11.4.11 PHILIPPINES
11.4.12 VIETNAM
11.4.13 REST OF ASIA-PACIFIC
11.5 MIDDLE EAST AND AFRICA
11.5.1 SAUDI ARABIA
11.5.2 EGYPT
11.5.3 KUWAIT
11.5.4 SOUTH AFRICA
11.5.5 UNITED ARAB EMIRATES
11.5.6 ISRAEL
11.5.7 REST OF MIDDLE EAST AND AFRICA
11.6 SOUTH AMERICA
11.6.1 BRAZIL
11.6.2 ARGENTINA
11.6.3 CHILE
11.6.4 PERU
11.6.5 REST OF SOUTH AMERICA
12 GLOBAL OBESITY TREATMENT MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 NOVO NORDISK A/S
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 ELI LILLY AND COMPANY
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT/NEWS
14.3 MEDTRONIC
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 BOSTON SCIENTIFIC CORPORATION
14.4.1 COMPANY SNAPSHOTS
14.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 JOHNSON & JOHNSON SERVICES, INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT/NEWS
14.6 ALTIMMUNE
14.6.1 COMPANY SNAPSHOT
14.6.2 PIPELINE PORTFOLIO
14.6.3 RECENT UPDATES
14.7 ASTRAZENECA
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT/NEWS
14.8 ALLURION
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
1.1.5 RECENT DEVELOPMENT/NEWS 421
14.9 AMGEN
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
1.1.13 RECENT DEVELOPMENT/NEWS 426
14.1 ARENA PHARMACEUTICALS LTD
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CURRAX PHARMACEUTICALS LLC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENT
14.12 COUSIN SURGERY
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENT
14.13 F. HOFFMANN-LA ROCHE LTD
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT/NEWS
14.14 FITTERFLY HEALTHTECH PVT. LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 PRODUCT PORTFOLIO
14.14.3 RECENT DEVELOPMENT
14.15 MORPHIC MEDICAL, INC
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENT
14.16 NOOM, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 OMADA HEALTH INC
14.17.1 COMPANY SNAPSHOT
14.17.2 PRODUCT PORTFOLIO
14.17.3 RECENT DEVELOPMENT
14.18 RESHAPE LIFESCIENCES
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
1.1.7 RECENT DEVELOPMENT/NEWS 445
14.19 RAZIEL
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 SPATZ FGIA INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 SANOFI
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
14.22 SANIONA
14.22.1 COMPANY SNAPSHOT
14.22.2 REVENUE ANALYSIS
14.22.3 PRODUCT PORTFOLIO
14.22.4 RECENT DEVELOPMENT
14.23 USGI MEDICAL
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENT
14.24 VIVUS LLC.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENT/NEWS
14.25 VIKING THERAPEUTICS
14.25.1 COMPANY SNAPSHOTS
14.25.2 REVENUE ANALYSIS
14.25.3 PRODUCT PORTFOLIO
14.25.4 RECENT DEVELOPMENT
14.26 ZEALAND PHARMA
14.26.1 COMPANY SNAPSHOT
14.26.2 REVENUE ANALYSIS
14.26.3 PRODUCT PORTFOLIO
14.26.4 RECENT DEVELOPMENT/NEWS
15 QUESTIONNAIRE
16 RELATED REPORTS
Tabellenverzeichnis
TABLE 1 OBESITY PREVALENCE BY REGION (ADULTS)
TABLE 2 OBESITY PREVALENCE BY GENDER (ADULTS)
TABLE 3 OBESITY PREVALENCE BY AGE (ADULTS)
TABLE 4 GLOBAL CLINICAL TRIAL MARKET FOR OBESITY TREATMENT
TABLE 5 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL OBESITY TREATMENT MARKET
TABLE 6 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL OBESITY TREATMENT MARKET
TABLE 7 GLOBAL OBESITY STATISTICS (2022)
TABLE 8 GLOBAL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 22 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 23 GLOBAL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 24 GLOBAL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 25 GLOBAL ADULT OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 26 GLOBAL GERIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 27 GLOBAL PEDIATRIC OBESITY TREATMENT IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 28 GLOBAL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 GLOBAL ONLINE PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 30 GLOBAL RETAIL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 31 GLOBAL WEIGHT MANAGEMENT CLINICS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 32 GLOBAL HOSPITAL PHARMACIES IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 GLOBAL WELLNESS & FITNESS CENTERS IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 34 GLOBAL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 GLOBAL CLASS III IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 36 GLOBAL CLASS II IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 37 GLOBAL CLASS I IN OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 38 GLOBAL OBESITY TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 NORTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 40 NORTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 NORTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 NORTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 43 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 44 NORTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 45 NORTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 46 NORTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 47 NORTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 48 NORTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 49 NORTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 NORTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 NORTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 52 NORTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 53 NORTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 U.S. OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 55 U.S. PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 U.S. CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 57 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 58 U.S. RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 59 U.S. COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 U.S. BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 61 U.S. BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 U.S. NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 63 U.S. INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 64 U.S. MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 U.S OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 66 U.S. OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 67 U.S. OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MEXICO OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 69 MEXICO PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MEXICO CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 72 MEXICO RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MEXICO COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 74 MEXICO BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 75 MEXICO BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MEXICO NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MEXICO INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 78 MEXICO MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 MEXICO OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 80 MEXICO OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 81 MEXICO OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 CANADA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 CANADA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 84 CANADA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 86 CANADA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 CANADA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 CANADA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 89 CANADA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 CANADA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 91 CANADA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 92 CANADA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 CANADA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 94 CANADA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 95 CANADA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 EUROPE OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 97 EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 EUROPE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 EUROPE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 EUROPE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 EUROPE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 103 EUROPE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 104 EUROPE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 EUROPE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 EUROPE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 EUROPE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 EUROPE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 109 EUROPE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 110 EUROPE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 UNITED KINGDOM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 UNITED KINGDOM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 UNITED KINGDOM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 UNITED KINGDOM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 UNITED KINGDOM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 UNITED KINGDOM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 118 UNITED KINGDOM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 UNITED KINGDOM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 UNITED KINGDOM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 121 UNITED KINGDOM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 UNITED KINGDOM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 123 UNITED KINGDOM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 UNITED KINGDOM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 GERMANY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 GERMANY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 GERMANY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 128 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 GERMANY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 GERMANY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 131 GERMANY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 132 GERMANY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 GERMANY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 134 GERMANY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 GERMANY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 GERMANY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 137 GERMANY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 138 GERMANY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 FRANCE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 FRANCE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 141 FRANCE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 142 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 FRANCE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 FRANCE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 145 FRANCE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 146 FRANCE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 FRANCE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 148 FRANCE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 149 FRANCE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 FRANCE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 151 FRANCE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 152 FRANCE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 153 ITALY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 ITALY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 ITALY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 ITALY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 ITALY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 ITALY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 160 ITALY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 ITALY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 ITALY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 ITALY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 ITALY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 165 ITALY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 166 ITALY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 SPAIN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 SPAIN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 SPAIN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 171 SPAIN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 SPAIN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 173 SPAIN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 174 SPAIN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 SPAIN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 SPAIN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 SPAIN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 SPAIN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 179 SPAIN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 180 SPAIN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 181 RUSSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 RUSSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 183 RUSSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 184 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 RUSSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 186 RUSSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 RUSSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 188 RUSSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 189 RUSSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 RUSSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 RUSSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 RUSSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 193 RUSSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 194 RUSSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 TURKEY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 TURKEY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 TURKEY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 TURKEY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 TURKEY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 201 TURKEY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 202 TURKEY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 203 TURKEY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 TURKEY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 TURKEY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 TURKEY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 207 TURKEY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 208 TURKEY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 NETHERLANDS OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 NETHERLANDS PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 NETHERLANDS CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 213 NETHERLANDS RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 214 NETHERLANDS COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 NETHERLANDS BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 216 NETHERLANDS BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 NETHERLANDS NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 218 NETHERLANDS INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 NETHERLANDS MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 NETHERLANDS OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 221 NETHERLANDS OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 222 NETHERLANDS OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 SWITZERLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 224 SWITZERLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 SWITZERLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 SWITZERLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 SWITZERLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 229 SWITZERLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 230 SWITZERLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 SWITZERLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 SWITZERLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 233 SWITZERLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 234 SWITZERLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 235 SWITZERLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 236 SWITZERLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 POLAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 POLAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 239 POLAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 241 POLAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 242 POLAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 POLAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 244 POLAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 245 POLAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 POLAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 247 POLAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 248 POLAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 249 POLAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 250 POLAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 IRELAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 IRELAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 IRELAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 IRELAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 IRELAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 257 IRELAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 258 IRELAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 IRELAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 IRELAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 IRELAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 IRELAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 263 IRELAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 264 IRELAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 AUSTRIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 AUSTRIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 AUSTRIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 268 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 AUSTRIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 AUSTRIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 271 AUSTRIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 272 AUSTRIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 AUSTRIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 274 AUSTRIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 AUSTRIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 AUSTRIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 277 AUSTRIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 278 AUSTRIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 NORWAY OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 280 NORWAY PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 281 NORWAY CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 283 NORWAY RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 284 NORWAY COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 285 NORWAY BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 286 NORWAY BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 NORWAY NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 288 NORWAY INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 289 NORWAY MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 NORWAY OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 291 NORWAY OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 292 NORWAY OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 REST OF EUROPE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 294 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 295 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 ASIA-PACIFIC PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 297 ASIA-PACIFIC CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 298 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 299 ASIA-PACIFIC RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 ASIA-PACIFIC COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 301 ASIA-PACIFIC BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 302 ASIA-PACIFIC BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 303 ASIA-PACIFIC NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 ASIA-PACIFIC INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 ASIA-PACIFIC MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 307 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 308 ASIA-PACIFIC OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 CHINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 CHINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 CHINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 313 CHINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 314 CHINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 315 CHINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 316 CHINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 CHINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 318 CHINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 CHINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 CHINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 321 CHINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 322 CHINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 JAPAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 324 JAPAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 JAPAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 JAPAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 328 JAPAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 329 JAPAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 330 JAPAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 331 JAPAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 JAPAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 333 JAPAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 334 JAPAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 335 JAPAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 336 JAPAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 INDIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 338 INDIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 339 INDIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 341 INDIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 342 INDIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 343 INDIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 344 INDIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 345 INDIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 INDIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 347 INDIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 348 INDIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 349 INDIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 350 INDIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 AUSTRALIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 AUSTRALIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 353 AUSTRALIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 AUSTRALIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 AUSTRALIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 357 AUSTRALIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 358 AUSTRALIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 AUSTRALIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 AUSTRALIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 AUSTRALIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 AUSTRALIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 363 AUSTRALIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 364 AUSTRALIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 SOUTH KOREA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 SOUTH KOREA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 SOUTH KOREA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 368 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 SOUTH KOREA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 SOUTH KOREA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 371 SOUTH KOREA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 372 SOUTH KOREA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 SOUTH KOREA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 374 SOUTH KOREA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 SOUTH KOREA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SOUTH KOREA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 377 SOUTH KOREA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 378 SOUTH KOREA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 TAIWAN OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 380 TAIWAN PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 381 TAIWAN CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 383 TAIWAN RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 384 TAIWAN COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 385 TAIWAN BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 386 TAIWAN BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 TAIWAN NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 388 TAIWAN INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 389 TAIWAN MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 TAIWAN OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 391 TAIWAN OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 392 TAIWAN OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SINGAPORE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 394 SINGAPORE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 395 SINGAPORE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 397 SINGAPORE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 398 SINGAPORE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 399 SINGAPORE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 400 SINGAPORE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SINGAPORE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SINGAPORE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 403 SINGAPORE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SINGAPORE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 405 SINGAPORE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 406 SINGAPORE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 MALAYSIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 MALAYSIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 MALAYSIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 MALAYSIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 MALAYSIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 413 MALAYSIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 414 MALAYSIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 MALAYSIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 MALAYSIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 MALAYSIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 418 MALAYSIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 419 MALAYSIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 420 MALAYSIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 421 THAILAND OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 THAILAND PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 THAILAND CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 424 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 THAILAND RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 THAILAND COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 427 THAILAND BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 428 THAILAND BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 THAILAND NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 430 THAILAND INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 431 THAILAND MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 THAILAND OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 433 THAILAND OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 434 THAILAND OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 INDONESIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 436 INDONESIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 INDONESIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 438 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 439 INDONESIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 INDONESIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 441 INDONESIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 442 INDONESIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 INDONESIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 444 INDONESIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 445 INDONESIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 INDONESIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 447 INDONESIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 448 INDONESIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 449 PHILIPPINES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 PHILIPPINES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 PHILIPPINES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 453 PHILIPPINES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 PHILIPPINES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 455 PHILIPPINES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 456 PHILIPPINES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 PHILIPPINES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 PHILIPPINES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 PHILIPPINES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 PHILIPPINES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 461 PHILIPPINES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 462 PHILIPPINES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 463 VIETNAM OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 464 VIETNAM PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 VIETNAM CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 VIETNAM RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 468 VIETNAM COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 469 VIETNAM BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 470 VIETNAM BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 471 VIETNAM NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 VIETNAM INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 VIETNAM MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 474 VIETNAM OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 475 VIETNAM OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 476 VIETNAM OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 REST OF ASIA-PACIFIC OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 478 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 479 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 480 MIDDLE EAST AND AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 481 MIDDLE EAST AND AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 483 MIDDLE EAST AND AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 484 MIDDLE EAST AND AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 485 MIDDLE EAST AND AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 486 MIDDLE EAST AND AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 MIDDLE EAST AND AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 488 MIDDLE EAST AND AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 489 MIDDLE EAST AND AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 491 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 492 MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 SAUDI ARABIA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 494 SAUDI ARABIA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 495 SAUDI ARABIA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 497 SAUDI ARABIA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 498 SAUDI ARABIA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 499 SAUDI ARABIA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 500 SAUDI ARABIA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 SAUDI ARABIA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 SAUDI ARABIA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 503 SAUDI ARABIA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 SAUDI ARABIA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 505 SAUDI ARABIA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 506 SAUDI ARABIA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 EGYPT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 EGYPT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 EGYPT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 EGYPT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 EGYPT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 513 EGYPT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 514 EGYPT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 EGYPT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 516 EGYPT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 EGYPT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 518 EGYPT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 519 EGYPT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 520 EGYPT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 521 KUWAIT OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 KUWAIT PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 KUWAIT CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 524 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 KUWAIT RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 KUWAIT COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 527 KUWAIT BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 528 KUWAIT BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 KUWAIT NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 530 KUWAIT INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 531 KUWAIT MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 KUWAIT OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 533 KUWAIT OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 534 KUWAIT OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 SOUTH AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 536 SOUTH AFRICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 SOUTH AFRICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 538 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 539 SOUTH AFRICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 SOUTH AFRICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 541 SOUTH AFRICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 542 SOUTH AFRICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 SOUTH AFRICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 544 SOUTH AFRICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 545 SOUTH AFRICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 SOUTH AFRICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 547 SOUTH AFRICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 548 SOUTH AFRICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 549 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 UNITED ARAB EMIRATES PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 UNITED ARAB EMIRATES CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 553 UNITED ARAB EMIRATES RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 UNITED ARAB EMIRATES COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 555 UNITED ARAB EMIRATES BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 556 UNITED ARAB EMIRATES BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 UNITED ARAB EMIRATES NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 UNITED ARAB EMIRATES INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 UNITED ARAB EMIRATES MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 561 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 562 UNITED ARAB EMIRATES OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 563 ISRAEL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 564 ISRAEL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 ISRAEL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 ISRAEL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 568 ISRAEL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 569 ISRAEL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 570 ISRAEL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 571 ISRAEL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 ISRAEL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 ISRAEL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 574 ISRAEL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 575 ISRAEL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 576 ISRAEL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 REST OF MIDDLE EAST AND AFRICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 578 SOUTH AMERICA OBESITY TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 579 SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 580 SOUTH AMERICA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 581 SOUTH AMERICA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 583 SOUTH AMERICA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 584 SOUTH AMERICA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 585 SOUTH AMERICA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 586 SOUTH AMERICA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 SOUTH AMERICA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 588 SOUTH AMERICA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 589 SOUTH AMERICA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 SOUTH AMERICA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 591 SOUTH AMERICA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 592 SOUTH AMERICA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 BRAZIL OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 594 BRAZIL PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 595 BRAZIL CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 597 BRAZIL RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 598 BRAZIL COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 599 BRAZIL BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 600 BRAZIL BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 BRAZIL NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 BRAZIL INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 603 BRAZIL MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 BRAZIL OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 605 BRAZIL OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 606 BRAZIL OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 ARGENTINA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 ARGENTINA PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 ARGENTINA CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 ARGENTINA RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 ARGENTINA COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 613 ARGENTINA BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 614 ARGENTINA BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 ARGENTINA NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 ARGENTINA INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 ARGENTINA MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 618 ARGENTINA OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 619 ARGENTINA OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 620 ARGENTINA OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 621 CHILE OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 CHILE PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 CHILE CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 624 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 CHILE RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 CHILE COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 627 CHILE BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 628 CHILE BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 CHILE NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 630 CHILE INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 631 CHILE MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 CHILE OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 633 CHILE OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 634 CHILE OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 PERU OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 636 PERU PHARMACOLOGICAL TREATMENT (ANTI-OBESITY DRUGS) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 PERU CENTRALLY ACTING ANORECTICS IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 638 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 639 PERU RESTRICTIVE SURGERIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 PERU COMBINATION SURGERIES IN OBESITY TREATMENT MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 641 PERU BARIATRIC SURGERY IN OBESITY TREATMENT MARKET, BY APPROACH, 2018-2032 (USD THOUSAND)
TABLE 642 PERU BEHAVIORAL & LIFESTYLE THERAPY IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 PERU NON-INVASIVE/ ENDOSCOPIC PROCEDURES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 644 PERU INTRAGASTRIC BALLOON (IGB) IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 645 PERU MEDICAL DEVICES & TECHNOLOGIES IN OBESITY TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 PERU OBESITY TREATMENT MARKET, BY AGE GROUP, 2018-2032 (USD THOUSAND)
TABLE 647 PERU OBESITY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 648 PERU OBESITY TREATMENT MARKET, BY PATIENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 649 REST OF SOUTH AMERICA OBESITY TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
Abbildungsverzeichnis
FIGURE 1 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL OBESITY TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL OBESITY TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL OBESITY TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL OBESITY TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL OBESITY TREATMENT MARKET: LIFELINE CURVE
FIGURE 7 GLOBAL OBESITY TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 GLOBAL OBESITY TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL OBESITY TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 GLOBAL OBESITY TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 GLOBAL OBESITY TREATMENT MARKET: SEGMENTATION
FIGURE 12 GLOBAL OBESITY TREATMENT MARKET EXECUTIVE SUMMARY
FIGURE 13 STRATEGIC DECISIONS
FIGURE 14 FIVE SEGMENTS COMPRISE THE GLOBAL OBESITY TREATMENT MARKET , BY TREATMENT TYPE
FIGURE 15 RISING PREVALENCE OF OBESITY IS EXPECTED TO DRIVE THE GROWTH OF GLOBAL OBESITY TREATMENT MARKET FROM 2025 TO 2032
FIGURE 16 THE PHARMACOLOGICAL TREATMENTS (ANTI-OBESITY DRUGS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL OBESITY TREATMENT MARKET IN 2025 - 2032
FIGURE 17 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL OBESITY TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 18 ASIA-PACIFIC IS THE FASTEST-GROWING MARKET FOR GLOBAL OBESITY TREATMENT MARKET IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 19 MARKET OVERVIEW
FIGURE 20 PREVALENCE OF OBESITY IN ADULTS AGE 20 AND OLDER, BY SEX AND AGE: UNITED STATES, AUGUST 2021–AUGUST 2023 SOURCE: CENTERS FOR DISEASE CONTROL AND PREVENTION.
FIGURE 21 SHARE OF PRE-OBESE AND OBESE PERSONS AGED 16 YEARS OR OVER, BY SEX, 2022 (%)
FIGURE 22 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 23 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 24 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 25 GLOBAL OBESITY TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 26 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2024
FIGURE 27 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, 2025-2032 (USD THOUSAND)
FIGURE 28 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, CAGR (2025-2032)
FIGURE 29 GLOBAL OBESITY TREATMENT MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 31 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 32 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 33 GLOBAL OBESITY TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 34 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2024
FIGURE 35 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 36 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, CAGR (2025-2032)
FIGURE 37 GLOBAL OBESITY TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 38 GLOBAL OBESITY TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 39 GLOBAL OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 40 NORTH AMERICA OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 41 EUROPE OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 42 ASIA-PACIFIC OBESITY TREATMENT MARKET: COMPANY SHARE 2024 (%)
Forschungsmethodik
Die Datenerfassung und Basisjahresanalyse werden mithilfe von Datenerfassungsmodulen mit großen Stichprobengrößen durchgeführt. Die Phase umfasst das Erhalten von Marktinformationen oder verwandten Daten aus verschiedenen Quellen und Strategien. Sie umfasst die Prüfung und Planung aller aus der Vergangenheit im Voraus erfassten Daten. Sie umfasst auch die Prüfung von Informationsinkonsistenzen, die in verschiedenen Informationsquellen auftreten. Die Marktdaten werden mithilfe von marktstatistischen und kohärenten Modellen analysiert und geschätzt. Darüber hinaus sind Marktanteilsanalyse und Schlüsseltrendanalyse die wichtigsten Erfolgsfaktoren im Marktbericht. Um mehr zu erfahren, fordern Sie bitte einen Analystenanruf an oder geben Sie Ihre Anfrage ein.
Die wichtigste Forschungsmethodik, die vom DBMR-Forschungsteam verwendet wird, ist die Datentriangulation, die Data Mining, die Analyse der Auswirkungen von Datenvariablen auf den Markt und die primäre (Branchenexperten-)Validierung umfasst. Zu den Datenmodellen gehören ein Lieferantenpositionierungsraster, eine Marktzeitlinienanalyse, ein Marktüberblick und -leitfaden, ein Firmenpositionierungsraster, eine Patentanalyse, eine Preisanalyse, eine Firmenmarktanteilsanalyse, Messstandards, eine globale versus eine regionale und Lieferantenanteilsanalyse. Um mehr über die Forschungsmethodik zu erfahren, senden Sie eine Anfrage an unsere Branchenexperten.
Anpassung möglich
Data Bridge Market Research ist ein führendes Unternehmen in der fortgeschrittenen formativen Forschung. Wir sind stolz darauf, unseren bestehenden und neuen Kunden Daten und Analysen zu bieten, die zu ihren Zielen passen. Der Bericht kann angepasst werden, um Preistrendanalysen von Zielmarken, Marktverständnis für zusätzliche Länder (fordern Sie die Länderliste an), Daten zu klinischen Studienergebnissen, Literaturübersicht, Analysen des Marktes für aufgearbeitete Produkte und Produktbasis einzuschließen. Marktanalysen von Zielkonkurrenten können von technologiebasierten Analysen bis hin zu Marktportfoliostrategien analysiert werden. Wir können so viele Wettbewerber hinzufügen, wie Sie Daten in dem von Ihnen gewünschten Format und Datenstil benötigen. Unser Analystenteam kann Ihnen auch Daten in groben Excel-Rohdateien und Pivot-Tabellen (Fact Book) bereitstellen oder Sie bei der Erstellung von Präsentationen aus den im Bericht verfügbaren Datensätzen unterstützen.
